PT813541E - PROCESS OF PRODUCTION OF A PROTEIN - Google Patents

PROCESS OF PRODUCTION OF A PROTEIN

Info

Publication number
PT813541E
PT813541E PT96906136T PT96906136T PT813541E PT 813541 E PT813541 E PT 813541E PT 96906136 T PT96906136 T PT 96906136T PT 96906136 T PT96906136 T PT 96906136T PT 813541 E PT813541 E PT 813541E
Authority
PT
Portugal
Prior art keywords
apoe
apoa
matrix
endotoxins
aqueous solution
Prior art date
Application number
PT96906136T
Other languages
Portuguese (pt)
Inventor
Hans Ageland
Lena Romander
Original Assignee
Esperion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esperion Therapeutics Inc filed Critical Esperion Therapeutics Inc
Publication of PT813541E publication Critical patent/PT813541E/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

A substantially endotoxin-free ApoA or ApoE is produced by recombinant DNA technique, suitably in E. coli. Medicaments and methods for treatment of atherosclerosis or cardiovascular diseases employ ApoA or ApoE purified by a process comprising contacting a first aqueous solution comprising ApoA or ApoE and endotoxins with a matrix comprising an immobilized compound with an end group comprising two or three nitrogen atoms bonded to a carbon atom for attaching the endotoxins to the matrix, and subsequently treating the matrix comprising the immobilized compound with a second aqueous solution comprising a surfactant for releasing the ApoA or ApoE while the endotoxins remain attached to the matrix. Alternatively, the ApoA or ApoE is purified by a process comprising contacting the first aqueous solution comprising ApoA or ApoE and endotoxins with an anion-exchange matrix for attaching the ApoA and ApoE to the matrix, treating the anion-exchange matrix with a second aqueous solution comprising a compound comprising two or three nitrogen atoms bonded to a carbon atom for releasing the endotoxins while the ApoA or ApoE remains attached to the matrix, and then releasing the ApoA or ApoE from the matrix.
PT96906136T 1995-03-03 1996-03-01 PROCESS OF PRODUCTION OF A PROTEIN PT813541E (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9500778A SE9500778D0 (en) 1995-03-03 1995-03-03 Process for producing a protein

Publications (1)

Publication Number Publication Date
PT813541E true PT813541E (en) 2003-09-30

Family

ID=20397430

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96906136T PT813541E (en) 1995-03-03 1996-03-01 PROCESS OF PRODUCTION OF A PROTEIN

Country Status (15)

Country Link
US (3) US5834596A (en)
EP (1) EP0813541B1 (en)
JP (1) JPH11501046A (en)
AT (1) ATE240348T1 (en)
AU (1) AU694623B2 (en)
CA (1) CA2212125A1 (en)
DE (1) DE69628148T2 (en)
DK (1) DK0813541T3 (en)
ES (1) ES2199284T3 (en)
IL (1) IL117320A (en)
NZ (1) NZ303325A (en)
PT (1) PT813541E (en)
SE (1) SE9500778D0 (en)
WO (1) WO1996027608A1 (en)
ZA (1) ZA961679B (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9500778D0 (en) * 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
SE9603068D0 (en) * 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603304D0 (en) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a compound
SE9603303D0 (en) * 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
DE19859703B4 (en) * 1998-12-23 2009-10-29 Macherey, Nagel Gmbh & Co. Handelsgesellschaft Process for purifying nucleic acids and anion exchangers for carrying out this process
CN1329359C (en) 1999-04-01 2007-08-01 埃斯佩里安医疗公司 Ether compounds, compositions, and uses thereof
US8568766B2 (en) * 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
CA2428114C (en) * 2000-11-10 2013-07-23 Proteopharma Aps Apolipoprotein analogues
EP1438060B1 (en) * 2001-09-28 2015-11-11 Esperion Therapeutics Inc. Prevention and treatment of restenosis by local administration of drug
US7470659B2 (en) 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
WO2003049685A2 (en) * 2001-12-07 2003-06-19 The Regents Of The University Of California Treatment for age-related macular degeneration
US20030229062A1 (en) * 2001-12-07 2003-12-11 The Regents Of The University Of California Treatments for age-related macular degeneration (AMD)
NZ537006A (en) * 2002-05-17 2008-01-31 Esperion Therapeutics Inc The use of apolipoprotein A-I Milano, for the manufacture ofa composition for treating preventing or reducing ischemic reperfusion injury in a tissue or organ
EP1597223B1 (en) 2003-01-23 2017-02-22 Esperion Therapeutics Inc. Hydroxyl compounds and compositions for cholesterol management and related uses
TW200526778A (en) * 2003-11-14 2005-08-16 Sembiosys Genetics Inc Methods for the production of apolipoproteins in transgenic plants
US20050176623A1 (en) * 2004-02-11 2005-08-11 Neil Wagle Non-invasive treatment of disease using amphipathic compounds
WO2005097206A2 (en) * 2004-04-06 2005-10-20 Cedars-Sinai Medical Center Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein a-i and apolipoprotein a-i milano
KR100560102B1 (en) * 2004-06-25 2006-03-13 한국생명공학연구원 Prophylactic and therapeutic agents containing point mutants of proapolipoprotein A-I for anti-atherosclerosis and anti-hyperlipidemia
EP2368561B1 (en) 2005-04-29 2013-12-04 The Regents of The University of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
EP2041174A2 (en) * 2006-06-16 2009-04-01 Lipid Sciences, Inc. Novel peptides that promote lipid efflux
US20080227686A1 (en) * 2006-06-16 2008-09-18 Lipid Sciences, Inc. Novel Peptides that Promote Lipid Efflux
US20080206142A1 (en) * 2006-06-16 2008-08-28 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
WO2008008872A2 (en) 2006-07-14 2008-01-17 Wisconsin Alumni Research Foundation Adsorptive membranes for trapping viruses
EP2049137A4 (en) 2006-08-08 2013-05-01 Univ California Salicylanilides enhance oral delivery of therapeutic peptides
WO2008039843A2 (en) * 2006-09-26 2008-04-03 Lipid Sciences, Inc. Novel peptides that promote lipid efflux
US8013122B2 (en) * 2006-12-20 2011-09-06 Kieu Hoang Method of purifying apolipoprotein A-1
CN100586958C (en) * 2006-12-20 2010-02-03 上海莱士血液制品股份有限公司 Method for preparing high-purity apolipoprotein A-I
AU2008296487A1 (en) 2007-08-28 2009-03-12 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
DK2682400T5 (en) 2007-08-28 2017-11-27 Uab Research Foundation Synthetic apolipoprotein E mimic polypeptides and methods of use
EP4241767A3 (en) 2008-11-10 2023-11-01 Arbutus Biopharma Corporation Novel lipids and compositions for the delivery of therapeutics
EP3243504A1 (en) 2009-01-29 2017-11-15 Arbutus Biopharma Corporation Improved lipid formulation
NZ594995A (en) 2009-03-12 2013-06-28 Alnylam Pharmaceuticals Inc LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HUMAN KINESIN FAMILY MEMBER 11 (Eg5) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) GENES
NZ621981A (en) 2009-05-05 2015-09-25 Tekmira Pharmaceuticals Corp Lipid compositions
HUE056773T2 (en) 2009-06-10 2022-03-28 Arbutus Biopharma Corp Improved lipid formulation
AP3574A (en) 2009-08-14 2016-02-08 Alnylam Pharmaceuticals Inc Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
CA2783372C (en) 2009-12-07 2019-07-16 Muthiah Manoharan Compositions for nucleic acid delivery
ES2749426T3 (en) 2009-12-18 2020-03-20 Univ British Columbia Nucleic Acid Administration Methods and Compositions
WO2011139911A2 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Lipid formulated single stranded rna
US20130137628A1 (en) 2010-05-11 2013-05-30 Esperion Therapeutics, Inc. Dimeric Oxidation-Resistant Apolipoprotein A1 Variants
IL300109A (en) 2010-06-03 2023-03-01 Alnylam Pharmaceuticals Inc Biodegradable lipids for the delivery of active agents
US20130202652A1 (en) 2010-07-30 2013-08-08 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
US20130323269A1 (en) 2010-07-30 2013-12-05 Muthiah Manoharan Methods and compositions for delivery of active agents
CN110123830A (en) 2010-11-09 2019-08-16 阿尔尼拉姆医药品有限公司 Composition and method for inhibiting the lipid of the expression of Eg5 and VEGF gene to prepare
WO2012099755A1 (en) 2011-01-11 2012-07-26 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
HUE041797T2 (en) 2011-02-07 2019-05-28 Cerenis Therapeutics Holding Sa Lipoprotein complexes and manufacturing and uses therof
WO2013049328A1 (en) 2011-09-27 2013-04-04 Alnylam Pharmaceuticals, Inc. Di-aliphatic substituted pegylated lipids
MX359171B (en) 2011-12-12 2018-09-18 Melior Pharmaceuticals I Inc Treatment of type i and type ii diabetes.
KR102067445B1 (en) * 2012-05-31 2020-01-17 에이전시 포 사이언스, 테크놀로지 앤드 리서치 Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives
US9610324B2 (en) 2012-07-11 2017-04-04 Esperion Therapeutics, Inc. Apolipoprotein mixtures
WO2015173633A2 (en) 2014-05-02 2015-11-19 Cerenis Therapeutics Holding Sa Hdl therapy markers
MX2017001432A (en) 2014-07-31 2017-05-09 Uab Res Found Apoe mimetic peptides and higher potency to clear plasma cholesterol.
BR112017019358A2 (en) 2015-03-13 2018-05-08 Esperion Therapeutics Inc fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
MA41793A (en) 2015-03-16 2018-01-23 Esperion Therapeutics Inc FIXED DOSE ASSOCIATIONS INCLUDING ETC1002 AND ONE OR MORE STATINS TO TREAT OR REDUCE A CARDIOVASCULAR RISK
CN107033237B (en) * 2017-05-11 2021-07-20 深圳市卫光生物制品股份有限公司 Separation and purification method of human plasma apolipoprotein A-I
MX2021015935A (en) 2019-06-21 2022-04-26 Esperion Therapeutics Inc Salt forms of bempedoic acid and methods for using the same.
WO2022035784A1 (en) * 2020-08-10 2022-02-17 Gel4Med, Inc. Antifungal matrix formed from peptide hydrogels

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587989B2 (en) * 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
JPS6196998A (en) 1984-10-16 1986-05-15 Mitsubishi Chem Ind Ltd Production of human apolipoprotein a-1-like protein
SE462100B (en) * 1985-08-08 1990-05-07 Perstorp Ab COMPOSITION AND ITS USE IN A TWO OR MULTIPLE SYSTEM
EP0262651A3 (en) * 1986-09-30 1990-06-20 Union Carbide Corporation Isolation of enzyme values from solution
GB8625435D0 (en) * 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
US5128318A (en) * 1987-05-20 1992-07-07 The Rogosin Institute Reconstituted HDL particles and uses thereof
GB8712540D0 (en) * 1987-05-28 1987-07-01 Ucb Sa Expression of human proapolipoprotein a-i
JP2606228B2 (en) * 1987-09-18 1997-04-30 三菱化学株式会社 Method for producing human proapolipoprotein AI-like protein
JP2561674B2 (en) 1987-10-06 1996-12-11 三菱化学株式会社 Method of producing protein
CA1335077C (en) * 1988-02-08 1995-04-04 Henri Isliker Process for the manufacture of apolipoproteins from human blood plasma or serum
JPH01238534A (en) * 1988-03-17 1989-09-22 Mitsui Toatsu Chem Inc Removal of endotoxin
EP0345155B1 (en) * 1988-05-31 1994-08-10 Mitsubishi Kasei Corporation Process for producing natural human apolipoprotein e-like proteins
DE3819463A1 (en) * 1988-06-08 1989-12-14 Behringwerke Ag EXPRESSION VECTORS FOR THE PRODUCTION OF UNFUSIONED PROTEINS IN MICROORGANISMS
IT1229996B (en) * 1989-04-20 1991-09-20 Cesare Sirtori EXPRESSION OF APOLIPOPROTEIN AI AND APOLIPOPROTEIN AI-MILAN IN YEAST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE APOLIPOPROTEINS.
KR960013134B1 (en) * 1989-10-31 1996-09-30 쉐링 코포레이션 E. coli secretory strains, plasmid, production process of polypeptides
SE468881B (en) * 1991-01-09 1993-04-05 Kabi Pharmacia Ab APPLICATION OF CERTAIN PHARMACEUTICALS FOR THE PREPARATION OF MEDICINAL PRODUCTS FOR TREATMENT OF ENDOTOXIN-INDEXED EFFECTS AND THE PREPARATION OF ENDOTOXINES FROM MISCELLANEOUS SOLUTIONS
WO1993000443A1 (en) * 1991-06-26 1993-01-07 Bio-Technology General Corp. Purification of recombinant apolipoprotein e from bacteria
SE9103701D0 (en) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab apolipoprotein
CA2137814A1 (en) * 1992-06-12 1993-12-23 Maryvonne Rosseneu New peptides and proteins, process for their preparation and their use as cholesterol acceptors
SE9203753D0 (en) * 1992-12-11 1992-12-11 Kabi Pharmacia Ab EXPRESSION SYSTEM FOR PRODUCING APOLIPOPROTEIN AI-M
JP3491917B2 (en) * 1993-02-05 2004-02-03 メビオール株式会社 Thermoreversible hydrogel material
US5643757A (en) * 1994-03-21 1997-07-01 American Cyanamid Company High yield production of human apolipoprotein A1 in E. coli.
JP3514514B2 (en) * 1994-06-14 2004-03-31 財団法人化学及血清療法研究所 Method for producing apolipoprotein A-1 from human plasma
SE9500724D0 (en) * 1994-06-23 1995-02-24 Pharmacia Ab Filtration
AU3151495A (en) * 1994-08-01 1996-03-04 James T Hsu Lipoprotein cholesterol assays
SE9500778D0 (en) * 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
US5672685A (en) * 1995-10-04 1997-09-30 Duke University Source of apolipoprotein E and method of isolating apolipoprotein E
SE9603068D0 (en) * 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein

Also Published As

Publication number Publication date
ATE240348T1 (en) 2003-05-15
EP0813541A1 (en) 1997-12-29
IL117320A0 (en) 1996-06-18
JPH11501046A (en) 1999-01-26
DK0813541T3 (en) 2003-09-15
ZA961679B (en) 1996-10-07
DE69628148D1 (en) 2003-06-18
ES2199284T3 (en) 2004-02-16
AU694623B2 (en) 1998-07-23
DE69628148T2 (en) 2004-01-08
AU4960796A (en) 1996-09-23
US5990081A (en) 1999-11-23
US5834596A (en) 1998-11-10
WO1996027608A1 (en) 1996-09-12
IL117320A (en) 2001-06-14
NZ303325A (en) 1998-12-23
SE9500778D0 (en) 1995-03-03
CA2212125A1 (en) 1996-09-12
EP0813541B1 (en) 2003-05-14
US6506879B1 (en) 2003-01-14

Similar Documents

Publication Publication Date Title
PT813541E (en) PROCESS OF PRODUCTION OF A PROTEIN
ES2155477T3 (en) CHROMATOGRAPHIC PURIFICATION AND NUCLEIC ACID SEPARATION PROCEDURE.
SE9603068D0 (en) Process for purifying a protein
DE69840678D1 (en) PROCESS FOR THE PRODUCTION OF PURIN NUCLEOSIDES BY FERMENTATION
DE69736981D1 (en) IN VITRO PROCESS FOR INTRODUCING NUCLEIC ACIDS INTO A CELL
CA2182388A1 (en) Process for producing endotoxin-free or endotoxin-poor nucleic acids and/or oligonucleotides for gene therapy
DE69433692D1 (en) METHOD FOR PRODUCING POLY-BETA-1-4-N-ACETYLGLUCOSAMINE
BG106768A (en) Process for the purification of pharmacologically active proteins by cation-exchange chromatography
BR9908186A (en) Process for producing endostatin
MY128271A (en) Purification method for (meth) acrylic acid
ATE131490T1 (en) METHOD FOR PRODUCING PURIFIED ALBUM SOLUTIONS
HUP9901418A2 (en) Process for racemisation of levobupivacaine and analogous agents
FR2632302B1 (en) PROCESS FOR RECOVERING CITRIC ACID FROM A LIQUOR CONTAINING IT
DE602004020632D1 (en) PROCESS FOR PREPARING AN ALPHA-1-ANTITRYPSINE SOLUTION
DE69902816T2 (en) SYNTHESIS OF HETEROPOLYL ACIDS
ATE278705T1 (en) METHOD FOR PURIFYING PROTEINS
ATE522617T1 (en) METHOD FOR PURIFYING INTERFERON BETA
HUP9901029A2 (en) Method for the production of rdspa alfa1
PT1001929E (en) PROCESS FOR THE MANUFACTURE OF 3-CYANO-2,4-DIHALOGENE-5-FLUOROBENZOIC ACIDS
RU95102320A (en) Process for purifying crude n-vinylpyrrolid-2-one
EP0446850A3 (en) Process for purifying recombinant human beta-interferon
DE3823519A1 (en) Process for the purification of activated protein C
DE69606959T2 (en) Process for the production of platelet factor-4
KR910015699A (en) Method of Purifying Lipocotin
FI916021A0 (en) Interferon purification method